上尿路尿路上皮癌治疗方式的选择

后森林; 侯俊清; 张建华; 王震; 杨邵昆; 陆伟

doi:10.13201/j.issn.1001-1420.2021.06.015

上尿路尿路上皮癌治疗方式的选择

- 1. 河南大学临床医学院(河南开封, 475000);
- 2. 信阳市中心医院泌尿外科
基金项目:
河南省科技发展计划项目(No:202102310429)

河南省医学科技攻关计划(联合共建)项目(No:LHGJ20190541)

河南大学研究生教育创新与质量提升计划项目(No:SYL20060193)

详细信息

通讯作者: 陆伟,E-mail:luweimed@163.com

中图分类号: R737.14

收稿日期: 2020-05-16

Selection of treatment for upper tract urothelial carcinoma

- 1. School of Clinical Medicine, Henan University;
- 2. Department of Urology, Central Hospital of Xinyang, Kaifeng, Henan, 475000, China

More Information

Corresponding author: LU Wei, E-mail: luweimed@163.com

Received Date: 16 May 2020

摘要

摘要: 上尿路尿路上皮癌是指发生于上尿路(肾盂或输尿管)的尿路上皮恶性肿瘤,目前外科治疗的金标准仍是根治性肾输尿管切除术联合膀胱袖状切除。但对于某些患者,如孤立肾、双侧肿瘤及肾功能不全的患者,在充分评估后也可实行保留肾脏的手术方式。无论是哪一种手术方式,术后局部药物灌注治疗都有一定的辅助疗效。但对于较为晚期的转移性患者,姑息性治疗则是不可避免的。
- 上尿路尿路上皮癌 /
- 根治性手术 /
- 保留肾脏手术 /
- 辅助治疗
Abstract: Upper tract urothelial carcinoma is a malignant urothelial neoplasm occurring in the upper urinary tract(renal pelvis or ureter). At present, the gold standard of surgical treatment is still radical nephroureterectomy combined with bladder cuff excision. However, for some patients, who have isolated kidneys, bilateral tumors or renal insufficiency, kidney-sparing surgery can also be performed after adequate evaluation. No matter what kind of operation, postoperative local drug infusion therapy has a certain auxiliary effect. However, palliative treatment is inevitable for patients with advanced metastatic disease.
- upper tract urothelial carcinoma /
- radical nephroureterectomy /
- kidney-sparing surgery /
- adjuvant treatment

HTML全文

参考文献(44)

[1]	Hasan MN,Rouprêt M,Keeley F,et al.Consultation on UTUC,Stockholm 2018 aspects of risk stratification:long-term results and follow-up[J].World J Urol,2019,37(11):2289-2296.
[2]	Bao Z,Du Y,Yuan Y,et al.Prevalence,clinicopathological features,and prognosis in upper tract urinary carcinoma patients with severe preoperative chronic kidney disease[J].Transl Androl Urol,2019,8(6):641-650.
[3]	Krabbe LM,Eminaga O,Shariat SF,et al.Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma[J].J Urol,2017,197(3 Pt 1):580-589.
[4]	Lughezzani G,Burger M,Margulis V,et al.Prognostic factors in upper urinary tract urothelial carcinomas:a comprehensive review of the current literature[J].Eur Urol,2012,62(1):100-114.
[5]	Campi R,Cotte J,Sessa F,et al.Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma:a multi-institutional experience[J].World J Urol,2019,37(11):2303-2311.
[6]	Moss TJ,Qi Y,Xi L,et al.Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma[J].Eur Urol,2017,72(4):641-649.
[7]	Hassler MR,Bray F,Catto J,et al.Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing:A Systematic Review of the Current Literature[J].Eur Urol,2020,78(2):209-220.
[8]	Clayman RV,Kavoussi LR,Figenshau RS,et al.Laparoscopic nephroure-terectomy:initial clinical case report[J].1991,1(6):343-349.
[9]	Jung H,Giusti G,Fajkovic H,et al.Consultation on UTUC,Stockholm 2018:aspects of treatment[J].World J Urol,2019,37(11):2279-2287.
[10]	刘荣耀,赵鹏举,李学松,等.经腹腔完全腹腔镜肾输尿管全长切除术治疗上尿路尿路上皮癌[J].北京大学学报(医学版),2011,43(4):531-534.
[11]	Azizi M,Cheriyan SK,Peyton CC,et al.Optimal Management of Upper Tract Urothelial Carcinoma:an Unmet Need[J].Curr Treat Options Oncol,2019,20(5):40.
[12]	王卫平,吴震杰,徐红,等.机器人全腹膜外肾输尿管全长及膀胱袖状切除术的初步临床应用[J].中华泌尿外科杂志,2018,39(3):161-165.
[13]	Leow JJ,Liu Z,Tan TW,et al.Optimal Management of Upper Tract Urothelial Carcinoma:Current Perspectives[J].Onco Targets Ther,2020,13:1-15.
[14]	Nazzani S,Preisser F,Mazzone E,et al.Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis[J].Eur Urol Focus,2020,6(2):298-304.
[15]	Dominguez-Escrig JL,Peyronnet B,Seisen T,et al.Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma:A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer[J].Eur Urol Focus,2019,5(2):224-241.
[16]	Moschini M,Foerster B,Abufaraj M,et al.Trends of lymphadenectomy in upper tract urothelial carcinoma(UTUC)patients treated with radical nephroureterectomy[J].World J Urol,2017,35(10):1541-1547.
[17]	Territo A,Foerster B,Shariat SF,et al.Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma:state of the art[J].Minerva Urol Nefrol,2018,70(3):242-251.
[18]	Foerster B,D'Andrea D,Abufaraj M,et al.Endocavitary treatment for upper tract urothelial carcinoma:A meta-analysis of the current literature[J].Urol Oncol,2019,37(7):430-436.
[19]	Hubosky SG,Boman BM,Charles S,et al.Ureteroscopic management of upper tract urothelial carcinoma(UTUC)in patients with Lynch Syndrome(hereditary nonpolyposis colorectal cancer syndrome)[J].BJU Int,2013,112(6):813-819.
[20]	Scotland KB,Kleinmann N,Cason D,et al.Ureteroscopic management of large ≥ 2 cm upper tract urothelial carcinoma:a comprehensive twenty-three year experience[J].Urology,2018,121:66-73.
[21]	陈业刚,林英立,郭战军,等.原发性下段输尿管尿路上皮癌保肾手术的可行性分析[J].中华泌尿外科杂志,2012,33(3):196-198.
[22]	Motamedinia P,Keheila M,Leavitt DA,et al.The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma:A 30-Year Comprehensive Experience[J].J Endourol,2016,30(3):262-267.
[23]	Musch M,Hohenhorst L,Pailliart A,et al.Robot-assisted reconstructive surgery of the distal ureter:single institution experience in 16 patients[J].BJU Int,2013,111(5):773-783.
[24]	Glinianski M,Guru KA,Zimmerman G,et al.Robot-assisted ureterectomy and ureteral reconstruction for urothelial carcinoma[J].J Endourol,2009,23(1):97-100.
[25]	Fang D,Seisen T,Yang K,et al.A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma[J].Eur J Surg Oncol,2016,42(11):1625-1635.
[26]	Seisen T,Peyronnet B,Dominguez-Escrig JL,et al.Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma:a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel[J].Eur Urol,2016,70(6):1052-1068.
[27]	Rouprêt M,Babjuk M,Burger M,et al.European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma:2020 Update[J].Eur Urol,2021,79(1):62-79.
[28]	Grasso M,Fishman AI,Cohen J,et al.Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma:a 15-year comprehensive review of 160 consecutive patients[J].BJU Int,2012,110(11):1618-1626.
[29]	Moschini M,Shariat SF,Rouprêt M,et al.Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies[J].J Urol,2018,199(5):1149-1157.
[30]	Heers H,DE Geeter P,Goebell PJ,et al.Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma-Subgroup Analysis of an Observational Study[J].Anticancer Res,2017,37(11):6437-6442.
[31]	Shao IH,Chang YH,Pang ST.Recent advances in upper tract urothelial carcinomas:From bench to clinics[J].Int J Urol,2019,26(2):148-159.
[32]	Campbell MT,Shah AY,Matin SF,et al.Optimizing management of upper tract urothelial carcinoma[J].Urol Oncol,2017,35(7):492-498.
[33]	Powles T,O'Donnell PH,Massard C,et al.Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma:Updated Results From a Phase 1/2 Open-label Study[J].JAMA Oncol,2017,3(9):e172411.
[34]	Bellmunt J,de Wit R,Vaughn DJ,et al.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J].N Engl J Med,2017,376(11):1015-1026.
[35]	Garje R,An J,Obeidat M,et al.Fibroblast Growth Factor Receptor(FGFR)Inhibitors in Urothelial Cancer[J].Oncologist,2020,25(11):e1711-e1719.
[36]	Perera T,Jovcheva E,Mevellec L,et al.Discovery and Pharmacological Characterization of JNJ-42756493(Erdafitinib),a Functionally Selective Small-Molecule FGFR Family Inhibitor[J].Mol Cancer Ther,2017,16(6):1010-1020.
[37]	Loriot Y,Necchi A,Park SH,et al.BLC2001 Study Group.Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma[J].N Engl J Med,2019,381(4):338-348.
[38]	Flaig TW,Spiess PE,Agarwal N,et al.Bladder Cancer,Version 3.2020,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2020,18(3):329-354.
[39]	Achkar T,Parikh RA.Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma[J].Urol Clin North Am,2018,45(2):257-266.
[40]	中国医师协会泌尿外科医师分会肿瘤专业委员会,中国医师协会泌尿外科医师分会上尿路尿路上皮癌(CUDA-UTUC)协作组.上尿路尿路上皮癌诊断与治疗中国专家共识[J].中华泌尿外科杂志,2018,39(7):485-488.
[41]	郑铎,刘隽垚,岳中瑾,等.上尿路尿路上皮癌术后膀胱灌注化疗的研究进展[J].中华泌尿外科杂志,2020,41(5):397-400.
[42]	Miyake M,Tatsumi Y,Matsumoto H,et al.Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma[J].BJU Int,2018,121(5):764-773.
[43]	吴肖冰,葛力源,戴黎阳,等.上尿路尿路上皮癌术后预防性膀胱灌注化疗的临床意义[J].中华泌尿外科杂志,2017,38(4):286-289.
[44]	Huang Y,Cen J,Liu Z,et al.A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas:A Retrospective 2-center Study[J].Technol Cancer Res Treat,2019,18:1533033819844483.